HIV Antivirals Market Size 2022 to 2032 | By Mylan, Lupin, Theratechnologies, Cipla, Pfizer, AbbVie

In 2022, the global HIV Antivirals market size is anticipated to be worth US$ 30.6 billion. The HIV Antivirals market is anticipated to reach US$ 47.0 billion by the end of 2032, with sales revenue growing at a 4.4% CAGR from 2022 to 2032. According to one recent prediction, fixed-dose combinations (FDCs) would account for more than 83% of the HIV Antivirals market in 2021.

The increased global prevalence of HIV is driving the demand for HIV Antivirals. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), around 37.7 million persons worldwide were infected with HIV in 2020.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15095

Furthermore, demand for HIV Antivirals will rise as the rate of unprotected sex and the usage of tainted needles or syringes rises. According to the Centres for Disease Control and Prevention’s (CDC) National Youth Risk Behaviour Survey, 38% of respondents had sexual intercourse, and 9% had four or more sexual partners in the United States during high school in 2019.

As a result, important players are creating generic anti-HIV medications at low cost in order to capitalise on rising demand. In the United States, for example, generic versions of Lamivudine, Abacavir, and Efavirenz are available at cheaper prices than branded ones. This is likely to generate a lucrative potential for generic HIV antiviral makers to provide poor and middle-income countries with affordable medical services.

Key Takeaways from Market Study

• Because of their ability to increase adherence to an HIV treatment regimen, fixed-dose combinations (FDCs) owned more than 83.2% of the market value in 2021.
• Hospital pharmacies are the dominant sales channel for HIV Antivirals, accounting for over 53.4% of the market in 2021, and are expected to increase at a CAGR of 4.5% over the next decade.
• In 2021, the United States dominated the North American HIV Antivirals market, with a total market share of around 96.8%.
• Because of the increasing number of HIV patients in the country, India is likely to lead the growth in the South Asian market.

“With increasing awareness among the people about HIV causes and symptoms, the HIV Antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.

For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-15095

Market Competition

Key Players:

• Merck & Co., Inc.
• Johnson & Johnson
• Genetech, Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie
• Cipla
• Pfizer Inc.
• Mylan N.V.
• Others

Market players are expanding the business through collaborations, and increasing involvement in clinical trials as the key strategy with instances of key companies, such as Merck and Gilead, in order to improve their reach in the market and compete with other key players in forthcoming years. For instance:

• Merck reported positive results from two pivotal Phase 3 trials of the experimental, once-daily oral fixed-dose combination tablet of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection in October 2021.
• Gilead announced in March 2021, in collaboration with Merck, the development and marketing of long-acting, experimental therapy combinations of Lenacapavir and Islatravir in HIV.

Expand Operations in the Future – To Get Requisite Details, Ask for a Custom Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-15095

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

• Fixed Dose Combinations (FDCs)
• Integrase Strand Transfer Inhibitors (INSTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry Inhibitors – CCR5 co-receptor antagonist
• Protease Inhibitors (PIs)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs